Champions Oncology, Inc. (CSBR) — 分析摘要
Champions Oncology, Inc.(CSBR)的市值为67.37百万美元,最近一年的营收同比增长了+4.4%。净利润率为-2.0%。当前市盈率为-57.8倍。
核心要点
- 营收同比变化+4.4%
- 净利润率-2.0%
- 市盈率-57.8倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比,CSBR的营收增长为+4.4%,市盈率为-57.8倍。
Champions Oncology, Inc. (CSBR)
前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示重点关注
当前存在需要关注的风险信号,应与估值结果一并解读。
最新报表显示自由现金流为负。
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
214
总部
BALTIMORE, MD
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。